

APPENDIX A

1. [Use of a D- or L-tryptophanyl-ester or its N-acyl derivative for producing a pharmaceutical composition for the prophylaxis and therapy of oxidative pathologic processes in degenerative diseases and/or cancer diseases.] A method for treating or preventing degenerative and/or cancer diseases caused by oxidative processes comprising the administration of a therapeutic amount of a composition comprising a D- or L-tryptophanyl-ester or its N-acyl derivative.

2. [Use] The method according to claim 1 or 14, wherein the D- or L-tryptophanyl-ester or its N-acyl derivative is [the following substance] selected from the group consisting of:

tryptophanoctyl-ester, tryptophandodecyl-ester, tryptophanstearyl-ester, tryptophanpalmityl-ester, tryptophanoleyl-ester, N-acetyl-tryptophanoctyl-ester, N-acetyl-tryptophandodecyl-ester, N-acetyl-tryptophanstearyl-ester, N-acetyl-tryptophanpalmityl-ester, N-acetyl-tryptophanoleyl-ester, N-dodecanoyl-tryptophanoctyl-ester, N-dodecanoyl-tryptophandodecyl-ester, N-dodecanoyl-tryptophanstearyl-ester, N-dodecanoyl-tryptophanpalmityl-ester, N-dodecanoyl-tryptophanoleyl-ester, N-acetyl-tryptophanethyl-ester, N-hexoyl-tryptophanethyl-ester, N-octoyl-tryptophanethyl-ester, N-dodecanoyl-tryptophanethyl-ester, N-stearoyl-tryptophanethyl-ester, N-palmitoyl-tryptophanethyl-ester or N-oleoyl-tryptophanethyl-ester.

3. [Use] The method according to claim 1 or 14, wherein the D- or

L-tryptophanethyl-ester or its N-acetyl derivative is selected from the group consisting of tryptophanoctyl-ester, N-oleoyl-tryptophanethyl-ester or N-dodecanoyl-tryptophanethyl-ester.

4. [Use] The method according to any one of claims 1 [to 3], 2 or 14 [for the treatment and/or prophylaxis of], wherein the disease is a neurodegenerative [diseases] disease.

5. [Use] The method according to claim 4, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, apoplectic fit or amyotrophic lateral sclerosis.

6. [Use] The method according to any one of claims 1 [to 3], 2 or 14 [for the treatment and/or prophylaxis], wherein the disease is [of cataracts] cataract.

7. [Use] The method according to claim 6, wherein the cataract is Cataracta senilis, Cataracta juvenilis, Cataracta diabetica or Cataracta complicata.

8. [Use] The method according to any one of claims 1 [to 3], 2 or 14 [for the treatment and/or prophylaxis of], wherein the disease is a neoplastic [diseases] disease.

9. [Use] The method according to claim 8, wherein the neoplastic disease is [the] selected from the group consisting of prostatic carcinoma, [the] mammary carcinoma, [the] liver carcinoma, [the] kidney carcinoma, [the] colon carcinoma, [the] gastric carcinoma [or] and [the] lung (bronchial) carcinoma.

10. [Use] The method according to any one of claims 1 [to 3], 2 or 14 [for the treatment and/or prophylaxis of], wherein the disease is a cardiovascular [diseases] disease.

11. [Use] The method according to claim 10, wherein the cardiovascular disease is arteriosclerosis or a myocardial infarction.

12. A pharmaceutical [Pharmaceutical] composition comprising a D- or

L-tryptophanyl-ester or its N-acyl derivative [according to any one of claims 1 to 3] for the prophylaxis and/or therapy of oxidative pathologic processes in degenerative and/or cancer diseases and, optionally, a pharmaceutically acceptable carrier, alone or in combination with [other] another antioxidatively effective pharmaceutical [compositions] composition or pharmaceutical [compositions] composition used with degenerative and/or cancer diseases.